Navigation Links
LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
Date:9/16/2010

BOZEMAN, Mont., Sept. 16 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc., a private, clinical-stage biopharmaceuticals company focused on the development of innovative vaccine products, announced today that it has initiated the first clinical trial for its bivalent intramuscular (IM) norovirus vaccine candidate, marking the fourth human clinical trial in the Company's norovirus virus-like particle (VLP) vaccine program.  The Phase I dose-escalation study will assess safety and immunogenicity associated with an IM formulation of LigoCyte's investigational vaccine in healthy adults. Clinical studies to date have shown a nasal formulation of a monovalent norovirus VLP vaccine to be immunogenic (i.e., having the ability to create an immune response) and generally well tolerated.

The bivalent vaccine formulation involved in the trial includes antigens from both norovirus genogroups that commonly infect humans. LigoCyte's bivalent vaccine is designed to provide protection against group I noroviruses with its GI.1 VLP antigen and against group II noroviruses with its GII.4 VLP antigen. Genogroup II.4 noroviruses are responsible for the majority of norovirus disease worldwide.  

"Norovirus infections are recognized as a widespread problem that can have very serious consequences," said Donald P. Beeman, CEO of LigoCyte.  "This bivalent norovirus vaccine is the first to be tested clinically, and the first GII.4 subtype antigen to be included in a human vaccine. Study of an intramuscular norovirus vaccine will continue to advance our norovirus program, which has been built on a nasally administered dry powder formulation. We have shown excellent results with the nasal vaccine to date, and investigation of multiple routes of administration will help us to select the best possible form of the product to prevent the burden of disease associated with
'/>"/>

SOURCE LigoCyte Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies
2. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
3. Data From LigoCytes Clinical Studies of Norovirus VLP Vaccine Presented at 13th Annual Conference on Vaccine Research
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... Sept. 29, 2014 EU5 Sigmoidoscopes Market ... report, "EU5 Sigmoidoscopes Market Outlook to 2020", provides ... The report provides value, in millions of US ... US dollars) within market segments - Flexible Video ... Flexible Non-Video (Fibre) Sigmoidoscopes). The report ...
(Date:9/29/2014)... 2014  Following US and European approvals of Elekta,s ... and Drug Administration (CFDA) has cleared the radiation therapy ... According to the International Agency for Research on ... cancer every year in China ... colorectal, liver and esophageal cancers 2 . Versa HD ...
(Date:9/29/2014)... , Sept. 29, 2014  Guerbet, a ... medical imaging, has received a Drug Shortage Assistance ... for its assistance in preventing or alleviating a ... for its efforts related to the shortage of ... drug application, submitting several post-approval supplements to restart ...
Breaking Medicine Technology:EU5 Sigmoidoscopes Market Outlook to 2020 2EU5 Sigmoidoscopes Market Outlook to 2020 3Chinese clinics and cancer patients to benefit from Elekta's Versa HD radiation therapy system 2Chinese clinics and cancer patients to benefit from Elekta's Versa HD radiation therapy system 3Guerbet Receives FDA's Drug Shortage Assistance Award: Recognized for contributions to address a shortage of Ethiodol (ethiodized oil) injection 2
... SUNNYVALE, California, September 23, 2010, ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Reata Pharmaceuticals Announce Agreement to Develop and... -- ABBOTT PARK, Ill. and IRVING, Texas, Sept. 23 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
Cached Medicine Technology:Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 2Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 3Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 4Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 5Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 6Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 7Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 8Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 9Health Language and HCL Technologies Partner to Offer ICD-10 Conversion Solution 10Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 2Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 3Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 4Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 5Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 6Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 7Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 8Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl for Chronic Kidney Disease Outside the U.S. 9
(Date:9/29/2014)... September 30, 2014 Foundations Recovery Network, ... announce the start of its 40th national conference by ... as a featured keynote speaker at the Moments of ... specializing in the fields of addiction and mental health ... Beach, Fla., September 29 – October 2, 2014, at ...
(Date:9/29/2014)... September 30, 2014 Atlantic NeuroSurgical Specialists ... their annual picnic to celebrate their strides in their fight ... at 6:00 p.m. at their Morristown office. , The annual ... 2012 and is a place where patients can find love, ... the picnic food and activities were enjoyed by guests, including ...
(Date:9/29/2014)... Garden City, NY (PRWEB) September 30, 2014 ... M.D., as a 2014 Professional Woman of the ... for leadership in gynecology and preventative medicine As the ... country, spanning virtually every industry and profession, the National ... community with over 600,000 members and nearly 300 Local ...
(Date:9/29/2014)... 29, 2014 Park Avenue Dental, a ... Dr. Michael A. Sherman who has dedicated his career ... care, has announced its inclusion in the Patient Connect ... patients access to private accounts so that they may ... Further, the system also allows patients to request appointments, ...
(Date:9/29/2014)... 2014 (PRWEB) September 29, 2014 Globally ... tablets and laptops provides the delivery of training, anyplace, ... youth to adult, to raise and enhance one’s job ... or to obtain certification in your chosen field. , ... to compete effectively and at MMU we make it ...
Breaking Medicine News(10 mins):Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 2Health News:Glenn Greenwald Addresses Drug Decriminalization at Foundations Recovery Network’s 40th National Conference 3Health News:Local Brain Tumor Foundation, ANS Center of Hope, Celebrates its Brain Cancer Patients 2Health News:National Association of Professional Women Announces Victoria J. Mondloch, M.D., Family Medicine and Women's Health, a 2014 Professional Woman of the Year 2Health News:Florida’s Park Avenue Dental Now Part of Intuitive Patient Connect 365 Dentist Search Portal 2Health News:Florida’s Park Avenue Dental Now Part of Intuitive Patient Connect 365 Dentist Search Portal 3Health News:MyMobileUniversity invites Corporations, Government Public Agencies, Academia, NGOs’ to Transform Workforce Development by Continued Education, Learning to Impact Lives 2Health News:MyMobileUniversity invites Corporations, Government Public Agencies, Academia, NGOs’ to Transform Workforce Development by Continued Education, Learning to Impact Lives 3
... 2009 The world,s top lung cancer specialists, medical ... Francisco, CA for the 13th World Conference on Lung ... Study of Lung Cancer (IASLC). Prevention and early detection ... remains one of the hardest cancers to detect in ...
... ... , ... August 2, 2009 -- United Benefit Advisors, LLC (UBA), one of the nation,s leading ... health management. , , , , ,"The majority of employers clearly recognize the potential ...
... cancer patients who have progressed on a cetuximab-containing regimen ... reported today at the annual meeting of the International ... cetuximab (Erbitux) and erlotinib (Tarceva) inhibit the epidermal growth ... once a patient progresses on one EGFR inhibitor they ...
... FRANCISCO, August 1, 2009 The world,s top lung ... week in San Francisco, CA for the 13th World ... Association for the Study of Lung Cancer (IASLC). According ... WCLC, targeted therapies, as first-line treatment, have the potential ...
... FASTRACK ... Billing & Home HealthCare Agency Billing Software System. The FASTRACK Integrated IV, HME ... single common Microsoft SQL database that allows for the connection of remote sites via ... ...
... ... by Richard K. Riegelman, is hard-wired to the Association of American Colleges ... The book is an important part of a growing movement of several ... as a critical component of good citizenship and a prerequisite for taking ...
Cached Medicine News:Health News:Diagnostic tools and innovative therapies improve patient prognosis 2Health News:Diagnostic tools and innovative therapies improve patient prognosis 3Health News:Diagnostic tools and innovative therapies improve patient prognosis 4Health News:Diagnostic tools and innovative therapies improve patient prognosis 5Health News:Diagnostic tools and innovative therapies improve patient prognosis 6Health News:Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 2Health News:Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs 3Health News:Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 2Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 3Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 4Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 5Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 6Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 7Health News:Advanced targeted therapies effective as first-line treatment for lung cancer 8Health News:Fastrack Release First Integrated HME Billing, Infusion Pharmacy & Home Care Agency Software in a Microsoft Environment 2Health News:New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 2Health News:New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 3
The PC3200h has three shelves and will hold three PF96h agitators. Total capacity is 288 random bags (96 apheresis bags)....
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
The PC2200i contains two shelves and will hold two PF96i agitators. It can store 192 random bags (64 apheresis bags)....
... rotators and agitators for continual ... set at 22C (71F) or ... (59F to 104F). Uniformity is ... bottom. Recorder is standard on ...
Medicine Products: